BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Patatsos K, Shekhar TM, Hawkins CJ. Pre-clinical evaluation of proteasome inhibitors for canine and human osteosarcoma. Vet Comp Oncol 2018;16:544-53. [PMID: 29998615 DOI: 10.1111/vco.12413] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Lei L, Zhang Y, Jian Q, Lei L, Lv N, Williamson RA, Chen P, Zhang D, Hu J. Resistance of osteosarcoma cells to the proapoptotic effects of carfilzomib involves activation of mitogen activated protein kinase pathways. Exp Physiol 2021;106:438-49. [PMID: 33336554 DOI: 10.1113/EP088762] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Harris MA, Hawkins CJ, Miles MA. Tetrazolium reduction assays under-report cell death provoked by clinically relevant concentrations of proteasome inhibitors. Mol Biol Rep 2020;47:4849-56. [PMID: 32424523 DOI: 10.1007/s11033-020-05530-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Machihara K, Namba T. Kuanoniamine C stimulates bortezomib-induced cell death via suppression of glucose-regulated protein 78 in osteosarcoma. Biochem Biophys Res Commun 2020;527:289-96. [PMID: 32446382 DOI: 10.1016/j.bbrc.2020.04.109] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
4 Marchandet L, Lallier M, Charrier C, Baud'huin M, Ory B, Lamoureux F. Mechanisms of Resistance to Conventional Therapies for Osteosarcoma. Cancers (Basel) 2021;13:683. [PMID: 33567616 DOI: 10.3390/cancers13040683] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
5 Harris MA, Miles MA, Shekhar TM, Cerra C, Georgy SR, Ryan SD, Cannon CM, Hawkins CJ. The Proteasome Inhibitor Ixazomib Inhibits the Formation and Growth of Pulmonary and Abdominal Osteosarcoma Metastases in Mice. Cancers (Basel) 2020;12:E1207. [PMID: 32403415 DOI: 10.3390/cancers12051207] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
6 Shekhar TM, Burvenich IJG, Harris MA, Rigopoulos A, Zanker D, Spurling A, Parker BS, Walkley CR, Scott AM, Hawkins CJ. Smac mimetics LCL161 and GDC-0152 inhibit osteosarcoma growth and metastasis in mice. BMC Cancer 2019;19:924. [PMID: 31521127 DOI: 10.1186/s12885-019-6103-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
7 Bloomer DT, Kitevska-Ilioski T, Pantaki-Eimany D, Ji Y, Miles MA, Heras B, Hawkins CJ. CrmA orthologs from diverse poxviruses potently inhibit caspases-1 and -8, yet cleavage site mutagenesis frequently produces caspase-1-specific variants. Biochem J 2019;476:1335-57. [PMID: 30992316 DOI: 10.1042/BCJ20190202] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
8 Torres HM, VanCleave AM, Vollmer M, Callahan DL, Smithback A, Conn JM, Rodezno-Antunes T, Gao Z, Cao Y, Afeworki Y, Tao J. Selective Targeting of Class I Histone Deacetylases in a Model of Human Osteosarcoma. Cancers (Basel) 2021;13:4199. [PMID: 34439353 DOI: 10.3390/cancers13164199] [Reference Citation Analysis]
9 Lilienthal I, Herold N. Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies. Int J Mol Sci 2020;21:E6885. [PMID: 32961800 DOI: 10.3390/ijms21186885] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 18.0] [Reference Citation Analysis]